HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reckitt reports personal-care growth

This article was originally published in The Rose Sheet

Executive Summary

UK-based Reckitt Benckiser says contribution of Mucinex expectorants helped drive 13% growth in its health and personal-care unit in the fourth quarter, to £567 mil. ($885.6 mil.). Division's net sales totaled $3.25 bil. for full fiscal 2009, a 14% gain, Reckitt reports. Initial sales of Lysol No-Touch Hand Soap System, which automatically dispenses antibacterial soap upon sensing the user's hand, were "very encouraging," CEO Bart Becht said during same-day analyst call. Firm plans to launch a line of Clearasil Overnight products in the first half of 2010 in multiple markets. Reckitt Benckiser booked overall revenue of $3.22 bil. in Q4, a 10% increase, and $12.11 bil. for the full year, up 8%. Adjusted earnings jumped 14% to $699.8 mil. for the quarter, and rose 13% to $2.21 bil. for the year

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016735

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel